Ionis Pharmaceuticals Inc news

   Watch this stock
Showing stories 1 - 10 of about 98   

Articles published

IONS 21.97 -1.63 (-6.91%)
price chart
Ionis Pharmaceuticals Inc (IONS) Sees Significant Increase in Short Interest
Ionis Pharmaceuticals logo Ionis Pharmaceuticals Inc (NASDAQ:IONS) was the recipient of a significant growth in short interest during the month of June.
Analyst's Focused Stocks: Codexis, Inc. (NASDAQ:CDXS) , Ionis ...  Street Updates
Stock Tracing Lower on the Week Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)  Engelwood Daily
Ionis Pharmaceuticals to Host R&D Day
Copies of these and other documents are available from the Company. In this press release, unless the context requires otherwise, "Ionis," "Company," "we," "our," and "us" refers to Ionis Pharmaceuticals and its subsidiaries. Ionis Pharmaceuticals™ is ...
2 Sizzling Hot Biotechnology Stocks: Sequenom Inc. (SQNM), Ionis ...  Zergwatch
Ionis Pharmaceuticals Inc (NASDAQ:IONS) Receives Average Rating of " ...  Community Financial News
Ionis Pharmaceuticals, Inc. Was Pummeled in May -- Here's Why
What: Shares of Ionis Pharmaceuticals (NASDAQ:IONS), a drug developer focusing on a broad spectrum of therapeutic ailments using its propriety antisense technology platform, were pummeled and lost 45% of their value in May, based on data from S&P ...
Today's Perilous Reversal Stock: Ionis Pharmaceuticals (IONS)
Ionis Pharmaceuticals Inc (IONS) Trading Down 5.1% After Insider Selling  Let Me Know About This
Better Buy: Celldex Therapeutics, Inc. vs. Ionis Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) doesn't look much better, with a drop of nearly 70% during the same period. Despite the nasty declines recently, one of these stocks just might be a good pick at its current price.
Ionis Investors And Management Should Focus On Success In Neurology  Seeking Alpha
Ionis's Stock Tanks as GSK Withdraws from Phase 3 Study  Yahoo Finance UK
Biotech Stocks Worth Chasing: Ionis Pharmaceuticals, Inc. (IONS), Varian ...
Ionis Pharmaceuticals, Inc. (IONS) ended last trading session with a change of 0.8 percent. It trades at an average volume of 2.55M shares versus 1.92M shares recorded at the end of last trading session.
Ionis Pharmaceuticals, Inc. Pipeline Review, Market Growth, Segment, Trends ...
“Ionis Pharmaceuticals, Inc. Global 2015 Clinical Trials Review, H2” provides an detailed overview of Ionis Pharmaceuticals, Inc. scenario. Report includes top line data relating on Ionis Pharmaceuticals, Inc. Global clinical trials scenario. This ...
Worth Watching Stock: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)
Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) reported earnings for the three months ended Mar 2016 on May 04, 2016. The company earned $-0.52 per share on revenue of $36.87M.
Ionis Pharmaceuticals Inc (IONS) Rating Reiterated by Needham & Company LLC  Community Financial News
Ionis Pharmaceuticals Inc (IONS) Given Buy Rating at Needham & Company LLC  Let Me Know About This
Ionis Pharmaceuticals Inc (NASDAQ:IONS) Has Propensity to Increase 171 Percent
Ionis Pharmaceuticals Inc (NASDAQ:IONS) shares traded 1.40% during the most recent session. Wall Street analysts covering the stock are projecting that the stock will reach $33.00 within the next 52-weeks.
Recommendation Trends of the Stock: Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)  News Oracle
Ionis Pharmaceuticals Inc Can't Be More Risky. Trades Sigfnicicantly Lower
The stock of Ionis Pharmaceuticals Inc (NASDAQ:IONS) is a huge mover today! The stock decreased 3.69% or $0.86 during the last trading session, hitting $22.46.
Ionis Shareholders Cannot Catch A Break
Ionis Pharmaceuticals (NASDAQ:IONS) investors seem to be unable to catch a break at the moment. After a rough few weeks of a major drug failing clinical trials, investors will now have to grapple with another piece of news.
Legal Dispute Puts Ionis Pharmaceuticals' Payday on Hold  Motley Fool
Judge Sides With Gilead Against Merck in Case Over Hepatitis C Drug Patents  Wall Street Journal